Goldman Sachs Starts Cubist Pharmaceuticals (CBST) at Conviction Buy, Sees 24% Upside

Go back to Goldman Sachs Starts Cubist Pharmaceuticals (CBST) at Conviction Buy, Sees 24% Upside